Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
31 July 2014Website:
http://www.adverum.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 20:21:32 GMTDividend
Analysts recommendations
Institutional Ownership
ADVM Latest News
Adverum Biotechnologies (ADVM) is currently considered oversold, suggesting that the intense selling pressure on the stock may be coming to an end. This, along with the consensus among Wall Street analysts in raising earnings estimates, points towards a possible turnaround for the stock in the near future.
Here is how Adverum Biotechnologies (ADVM) and Cigna (CI) have performed compared to their sector so far this year.
Adverum (ADVM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
The heavy selling pressure might have exhausted for Adverum Biotechnologies (ADVM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
The heavy selling pressure might have exhausted for Adverum Biotechnologies (ADVM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Here is how Adverum Biotechnologies (ADVM) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
There are plenty of penny stocks ready to pop. However, we have to remember that penny stocks are extremely risky, and can be costly in the end.
- Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47 th Annual Meeting of the Macula Society, with company-sponsored webcast on Thursday, February 8, 2024 at 8:00am ET -
Here, we discuss some reasons why buying Adverum Biotechnologies (AQST) stock now may turn out to be a prudent move.
What type of business is Adverum Biotechnologies?
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
What sector is Adverum Biotechnologies in?
Adverum Biotechnologies is in the Healthcare sector
What industry is Adverum Biotechnologies in?
Adverum Biotechnologies is in the Biotechnology industry
What country is Adverum Biotechnologies from?
Adverum Biotechnologies is headquartered in United States
When did Adverum Biotechnologies go public?
Adverum Biotechnologies initial public offering (IPO) was on 31 July 2014
What is Adverum Biotechnologies website?
https://www.adverum.com
Is Adverum Biotechnologies in the S&P 500?
No, Adverum Biotechnologies is not included in the S&P 500 index
Is Adverum Biotechnologies in the NASDAQ 100?
No, Adverum Biotechnologies is not included in the NASDAQ 100 index
Is Adverum Biotechnologies in the Dow Jones?
No, Adverum Biotechnologies is not included in the Dow Jones index
When does Adverum Biotechnologies report earnings?
The next expected earnings date for Adverum Biotechnologies is 09 August 2024